ACM
ACAD icon

Anfield Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Anfield Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-177
Closed -$3.27K – 405
2024
Q1 		$3.27K Buy
+177
New +$4.38K ﹤0.01% 228

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Anfield Capital Management's ACAD Position: Q2 2024 in Review

Anfield Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 177 shares — an estimated $3.27K sold.

Anfield Capital Management first reported a position in ACAD in Q1 2024 and held it in 1 quarter. The position peaked at $3.27K in Q1 2024. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Anfield Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Anfield Capital Management sold 177 Acadia Pharmaceuticals shares in Q2 2024, an estimated $3.27K.
  • Anfield Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Anfield Capital Management's Acadia Pharmaceuticals position peaked at $3.27K in Q1 2024.
  • 264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Anfield Capital Management's 13F filing for Q2 2024, filed 31 Jul 2024.